IVVD logo

IVVD Invivyd, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$0.47
-0.04 (-8.21%)

Invivyd, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention…

Market Cap: $138.68Mwww.invivyd.com

Price

No data yet.

Social Signal Score

43
5d
50
1 mentions
—
30d
37
3 mentions
—
60d
43
10 mentions
—
90d
43
13 mentions
—
news: 13

Analyst Ratings

8 analysts
Buyconsensus
Strong Buy 0Buy 5Hold 3Sell 0Strong Sell 0
Avg price target$9.5+1919.1%
Low $9Median $9.5High $10
Current Consensus

Revenue

$15.45M
$0.00$5.74M$11.47M$17.21M
Jun 2020Sep 2026

Analyst Estimates

FY2025
$-0.39
$-0.45–$-0.32
2 analysts
FY2026
$-0.50
$-0.55–$-0.45
1 analysts
FY2027
$-0.33
$-0.42–$-0.24
1 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Marc William Elia
Sector
Healthcare
Industry
Biotechnology
Employees
122
Beta
0.71
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
-6.93
www.invivyd.com